SPRYCEL (dasatinib)Effekt

In newly diagnosed CML patients compared to imatinib SPRYCEL®(dasatinib) provides fast and deep responses early in treatment.1, 2

Higher efficacy for Sprycel vs imatinib at 3 months1,2


Higher rates of MMR vs imatinib sustained through 5-year follow-up 2

CA180-056 5-year follow-up data 2

Time to MMR is faster for Sprycel®: more patients achieve deep molecular response vs imatinib 2,3

 


Referenser

  1. Jabbour et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 23 January 2014, 123:494-500.
  2. SPRYCEL(dasatinib) SPC, www.fass.se
  3. Cortés JE. Blood. Nov 14, 2014. Vol.124.no.21:abs 152